REAL LIFE DATA FROM THE FIRST LINE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA: EXPERIENCE OF A THIRD LEVEL CENTER

被引：0
|
作者：
Sanchez-Raga, J. M. [1 ]
Perez-Montana, A. [1 ]
Beltran, N. [1 ]
Ros, T. [1 ]
Boyeras, B. [1 ]
Martorell, C. [1 ]
Gutierrez, A. [1 ]
Sampol, A. [1 ]
机构：
[1] Hosp Univ Son Espases, Palma De Mallorca, Spain
来源：
HAEMATOLOGICA | 2019年 / 104卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO-008
引用
收藏
页码：194 / 194
页数：1
相关论文
共 50 条
  • [41] DESCRIPTIVE ANALYSIS OF THE CARFILZOMIB EFFECTIVENESS PROFILE IN PATIENTS WITH MULITPLE MYELOMA. EXPERIENCE IN A THIRD LEVEL CENTER
    Cuellar Perez-Avila, C.
    Gutierrez Lopez de Ocariz, X.
    Poza Sanaella, M.
    Zamanillo Herero, I
    Iniguez Garcia, R.
    Alonso Fernandez, R.
    Sanchez Pina, J. M.
    Gonzalez Medina, J.
    Buendia Urena, B.
    De Nicolas Sol, R.
    Vera Guerrero, E.
    Hidalgo Soto, M.
    Lopez Munoz, N.
    Lahuerta Palacios, J. J.
    Martinez Lopez, J.
    HAEMATOLOGICA, 2019, 104 : 202 - 203
  • [42] ANTITHROMBOTIC TREATMENTS IN THE REAL LIFE OF PATIENTS WITH MULTIPLE MYELOMA IN THERAPY WITH IMMUNOMODULANTS: A MONOCENTRIC EXPERIENCE
    Antolino, G.
    La Verde, G.
    Leporace, A.
    Mariani, S.
    Togni, C.
    Tafuri, A.
    HAEMATOLOGICA, 2021, 106 (10) : 168 - 168
  • [43] EXPERIENCE OF A CENTER IN THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA NOT CANDIDATES TO TRANSPLANT IN 1ST LINE. IS IT NECESSARY TO INCORPORATE CONTINUOUS TREATMENT?
    Suarez, A.
    Luzardo, H.
    Guerra, L.
    Perera, M.
    Torres, M.
    Cruz, N.
    Gonzalvez, J.
    Perez, L.
    Gomez Casares, M. T.
    Lemes, A.
    Gonzalez, E.
    Saez Maria, N.
    Molero, T.
    HAEMATOLOGICA, 2018, 103 : 309 - 310
  • [44] DARATUMUMAB AS A COMBINATION TREATMENT IN PATIENTS WITH RELAPSING MULTIPLE MYELOMA: REAL LIFE OUTCOMES
    Perez Montana, A.
    Sanchez Raga, J. M.
    Beltran Serra, N.
    Ros Mateu, T.
    Sampol Mayol, A.
    HAEMATOLOGICA, 2018, 103 : 118 - 119
  • [45] Treatment Patterns and Clinical Outcomes Across Consecutive Treatment Lines in Multiple Myeloma Patients: Single-Center Real World Experience
    Trestman, Svetlana
    Avivi, Irit
    Mittelman, Moshe
    Levi, Shai
    Cohen, Yael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E251 - E252
  • [46] A SINGLE-CENTER REAL-LIFE EXPERIENCE WITH BELANTAMAB MAFODOTIN IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Condorelli, A.
    Garibaldi, B.
    Gagliano, C.
    Romano, A.
    Ragusa, M.
    Del Fabro, V.
    Parrinello, N. L.
    Longo, A.
    Cosentino, S.
    Di Raimondo, F.
    Conticello, C.
    HAEMATOLOGICA, 2021, 106 (10) : 169 - 169
  • [47] Efficacy and safety of lenalidomide in relapse/refractory multiple myeloma—Real life experience of a tertiary cancer center
    Cristina João
    Inês Coelho
    Carlos Costa
    Susana Esteves
    Paulo Lucio
    Annals of Hematology, 2015, 94 : 97 - 105
  • [48] First line and salvage therapy with total therapy 3-based treatment for multiple myeloma-An extended single center experience
    Muchtar, Eli
    Ram, Ron
    Raanani, Pia
    Yeshurun, Moshe
    Oniashvili, Nino
    Shpilberg, Ofer
    Magen, Hila
    LEUKEMIA RESEARCH, 2014, 38 (12) : 1401 - 1406
  • [49] EFFICACY AND SAFETY OF LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL LIFE EXPERIENCE FROM TURKEY
    Saydam, G.
    Soyer, N.
    Patir, P.
    Uysal, A.
    Duran, M.
    Durusoy, R.
    Sahin, F.
    Vural, F.
    Tobu, M.
    Tombuloglu, M.
    HAEMATOLOGICA, 2017, 102 : 784 - 784
  • [50] LENALIDOMIDE/DEXAMETHASONE COMBINATION AS FIRST-LINE ORAL THERAPY OF FRAIL MULTIPLE MYELOMA PATIENTS: AN UNICENTRIC REAL LIFE STUDY
    Del Fabro, V.
    Leotta, V.
    Di Giorgio, M. A.
    Bellofiore, C.
    Markovic, U.
    Romano, A.
    Orofino, A.
    Bulla, A.
    Curtopelle, A.
    Elia, F.
    Di Raimondo, F.
    Conticello, C.
    HAEMATOLOGICA, 2022, 107 : 85 - 85
12345